详情页

当前位置：首页 > 详情页

Effect of Neoadjuvant CAF Regimen on the Expression of BCSG1 in Breast Cancer

文献详情

资源类型：

作者：

机构： [1]Laboratory of Experimental Pathology, Hebei Medical University, Shijiazhuang 050011, China [2]Department of Pathology, the Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang 050011, China

出处：

DOI：

ISSN：

关键词： breast cancer neoadjuvant chemotherapy immunohistochemistry BSCG1

摘要：

Objective: To evaluate the efficacy of neoadjuvant chemotherapy and explore a sensitive and objective way in the evaluation of neoadjuvant chemotherapy, the pathological changes and BCSG1 expression were studied by pathological and immunohistochemical method in breast cancer patients with CAF neoadjuvant chemotherapy (Cyclophosphamide, Adriamycin and Fluorouracil, CAF) and those without at the same period. Methods: Specimens were obtained from 34 breast cancer patients receiving neoadjuvant CAF regimen chemotherapy (CAF group) and 110 breast cancer patients not receiving neoadjuvant chemotherapy (control group). The BCSG1 expression was detected by SP immunohistochemistry.Correlation between BCSG1 expression and pathological response to CAF neoadjuvant chemotherapy was analyzed. Results: Overall response rate to neoadjuvant chemotherapy was 79.4%. The strong cytoplasm expression of BCSG1 was significantly lower in CAF group than in control group (29.4% vs. 64.5%,P＜0.01). In CAF group, the positive cytoplasm expression in partial response (PR) (grade Ⅱ) cases was significantly lower than that in no response (NR) (grade Ⅲ) cases (P=0.002). Conclusion: Neoadjuvant chemotherapy of CAF regimen could decrease the nuclear expression of BSCG1 in breast cancer.

基金：

语种：

第一作者：

第一作者机构： [1]Laboratory of Experimental Pathology, Hebei Medical University, Shijiazhuang 050011, China

通讯作者：

通讯机构： [1]Laboratory of Experimental Pathology, Hebei Medical University, Shijiazhuang 050011, China [*1]Laboratory of Experimental Pathology, Hebei Medical University, Shijiazhuang 050011, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） [2]Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer [3]Residual Tumor Histology after Neoadjuvant Chemotherapy: A Novel Approach to Risk Stratification in Breast Cancer [4]Expression of BCRP/ABCG2 Protein in Invasive Breast Cancer and Response to Neoadjuvant Chemotherapy [5]Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer [6]A study focusing on the relationship between tumour regression patterns and prognosis after neoadjuvant chemotherapy for breast cancer [7]The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis [8]乳腺癌组织中BCRP的表达与新辅助化疗疗效的关系 [9]Artificial intelligence for assisted HER2 immunohistochemistry evaluation of breast cancer: A systematic review and meta-analysis [10]A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer, residual disease in breast and nodes combined with Ki-67 (RDBN-K)